HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
BenzingaNov 6, 2023 07:05 ET
Aridis Pharmaceuticals Analyst Ratings
BenzingaNov 6, 2023 07:04 ET
Promising Developments and Value Proposition: A Buy Rating Analysis of Aridis Pharmaceuticals
TipRanksNov 6, 2023 06:33 ET
Aridis Pharmaceuticals Analyst Ratings
BenzingaOct 20, 2023 13:52 ET
Maxim Group Sticks to Its Hold Rating for Aridis Pharmaceuticals (ARDS)
TipRanksJan 27, 2023 15:09 ET
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)
TipRanksJan 26, 2023 06:37 ET
Aridis Pharmaceuticals Analyst Ratings
Benzinga Analyst RatingsJan 26, 2023 06:15 ET
HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $10
Benzinga Real-time NewsJan 26, 2023 06:15 ET
Aridis Pharmaceuticals (ARDS) Gets a Buy From H.C. Wainwright
TipRanksDec 12, 2022 13:05 ET
Analysts' Top Healthcare Picks: Aridis Pharmaceuticals (ARDS), Minerva Neurosciences (NERV)
TipRanksAug 22, 2022 13:10 ET
Aridis Pharmaceuticals Cut to Hold From Buy by Maxim Group
Dow JonesAug 16, 2022 12:18 ET
Aridis Pharmaceuticals Analyst Ratings
Benzinga Analyst RatingsAug 16, 2022 12:08 ET
No Data
No Data